scp hip outcomes study

Conditions: Subchondral Cysts; Subchondral Bone Edema; Bone Marrow Edema; Insufficiency Fractures; Avascular Necrosis of Hip; Femoroacetabular Impingement; Dysplasia; Hip

Summary: post-market clinical outcomes study to collect data on the short- and long-term outcomes for subjects who are undergoing or have undergone the subchondroplasty® (scp®) procedure in the hip in a standard clinical setting. outcomes to be assessed include medication usage, pain, function, activity levels and patient satisfaction.

this study is designed as a post-market, single arm, non-randomized multi-center investigation. male and female subjects, at least 18 years of age, with at least one subchondral bone defect in the form of a cyst and/or bone marrow lesion (bml), insufficiency fracture or bone defect associated with early stage avascular osteonecrosis (avn) in the femoral head, femoral neck and/or acetabulum who are suitable candidates for use of accufill during the subchondroplasty procedure are eligible for enrollment in this study. a maximum of 15 study sites, in the united states of america, will enroll a target of 50 subjects. each investigator must obtain irb approval, or favorable opinion by an ec, prior to consent of the first subject; no study-related procedures can occur without the approval and oversight of a registered irb or ec. if the study site does not have an irb of record, a central irb may be utilized upon approval by zimmer biomet. demographics, medical history, hip history and use of pain medication and therapy will be recorded at the time of subject consent. additionally, patient reported outcomes measures will be obtained pre-operatively. operative details including the scp procedure, concomitant surgical procedures and intraoperative safety events will be recorded at the time of surgery. prospective subjects will be considered enrolled in this study once their subchondroplasty procedure has been performed. subjects will complete only the numeric pain scale at 2 weeks post-operatively. thereafter, subjects will complete self-reported outcomes measures post-operatively at 6 weeks, 12 weeks, 6 months, 1 year and 2 years. these measures include information on pain medication and therapy, pain levels, function, activity and subject satisfaction. screening for adverse events and conversion will occur throughout the study. subjects will complete the study at 2 years or will be withdrawn if they undergo conversion of the subchondroplasty site. for the purposes of this protocol, a conversion will be defined as total hip arthroplasty or any procedure involving removal of the accufill material on the index hip.

Eligibility criteria:
inclusion criteria: * candidates must meet all of the following: 1. surgeon considers the patient appropriate for the scp procedure of the hip. 2. subchondral bone defect(s) in the femoral head, femoral neck and/or acetabulum has been confirmed via radiographic finding on mri or x-ray. 3. subject provides voluntary signature on the irb approved informed consent form. 4. subject is at least 18 years of age. 5. subject must be physically and mentally willing and able, in the investigator's opinion at the time of enrollment, to be compliant with the protocol and complete outcome forms via email, telephone, in-person or by regular mail. exclusion criteria: * candidates will be excluded if they meet any of the following: 1. subject has collapse of subchondral bone. 2. subject is pregnant at the time of surgery. 3. subject is incarcerated. 4. subject is involved in active litigation related to the condition being treated. 5. subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available language for the pros in the protocol.

Keywords: subchondroplasty bone marrow lesion arthroscopy bone substitute material accufill subchondral bone defect